MDCSCO is dedicated to ensuring you stay informed during the COVID-19 crisis. Click above to find all of the latest resources from ASCO, ASH, COA, HOSS, and important Industry News related to the crisis.

COVID-19 News Specific to MDCSCO Members:

Financial Resources for Maryland Businesses, Find out more

BREAKING NEWS: National healthcare organizations urge Governors and Insurance Commissioners throughout the country to support broad coverage and payment of telemedicine services even after the COVID-19 pandemic ends. Read the letters to the Governors and the Insurance Commissioners here.

The Maryland and District of Columbia Society of Clinical Oncology, Inc. (“MDCSCO”) is committed to improving the quality and delivery of care in medical oncology in the State of Maryland and the District of Columbia. We promote appropriate standards of care in oncology and cooperate with investigators conducting cancer research.

In addition, we assist in the continuing education of oncologists and educate the public, the government, insurance carriers, and other health care providers about appropriate prevention of cancer and other therapeutic options for patients with cancer.

We encourage you to join more than 400 current members in providing the leadership in our progressive future. Click here to find out more about our membership.


2020 Annual Report

 Membership Benefits

Membership is Now FREE for
Members and for Allied

Click here to join!

MDCSCO is sharing this table containing telemedicine updates with the permission of the compiler. While this content is thought to be reliable, we suggest you verify the accuracy before taking action based on this information.

Click here to view the table.

CDC is working across the Department of Health and Human Services and across the U.S. government in the public health response to COVID-19.
Please see links below for additional information:


As of January 1, 2021, there will be significant changes to the office and outpatient Evaluation and Management (E&M) services (CPT ® codes 99202-99215) for both new and established patients.

Find out more




The Maryland and District of Columbia Society of Clinical Oncology now offers FREE professional memberships to physician oncologists. Click here for the flyer.

As a member, you get the following benefits:

  • Free attendance at ALL MDCSCO events.
  • A legislative voice on issues of high priority to the practice of oncology.
  • Being a member of one of the U.S.'s strongest ASCO state affiliates and representation at ASCO.
  • Representation at NCCN.
  • Opportunity to be considered for elected office and other leadership roles within MDCSCO.

Confirm your membership now!



RxVantage recently shared a panel discussion of oncology experts from around the country who have exhibited impressive leadership amid COVID-19. These executives met via video conference to share experiences, discuss strategies that have worked (as well as those that have not), and their plans for moving forward. Click below to view each presentation:



Public Affairs Event

April 29, 2021, 7:00 pm
FREE Virtual Event for Allied Professionals and Physicians
Register HERE.



June 16, 2021 - ASCO Update (virtual) - 7:00 p.m. followed by reception
September 29, 2021 - Hot Topics (tentatively scheduled as an in-person event) - 6:15 p.m. reception, followed by dinner and program
October 28, 2021 - Membership and Awards Dinner (tentatively scheduled as an in-person event) 6:15 p.m. reception, followed by dinner and program

Resources - COVID-19 Vaccinations for Physicians

District of Columbia:


Most Favored Nation Interim Final Rule Will Devastate Cancer Care

The American Society of Clinical Oncology (ASCO) filed an amicus curiae brief in support of motions in three cases to stop the Most Favored Nation (MFN) model from taking effect on January 1, 2021. ASCO’s brief urges the court to stop implementation of the model, citing its devastating impact on patients. CMS projects that the model will cause 19% of beneficiaries to lose access to its 50 targeted drugs, 38 of which are used in cancer treatment. In addition, ASCO estimates that independent community oncology practices will see a 52% average loss of Medicare drug revenue once the model is fully phased in and that hospital outpatient oncology departments will see an average loss of 50% by year four of the model. Read the Society’s full amicus curiae brief and comments submitted to CMS about the MFN Model.

Current News

  • January 7, 2011 - Congress recently passed an end-of-year legislative package that provides federal funding for Fiscal Year (FY) 2021 and includes numerous provisions that will directly impact patients with cancer and their entire cancer care team. Find out more
  • December 10, 2020 - Community Oncology Alliance Applauds Supreme Court Ruling Supporting State Regulations of PBMs, Find out more
  • October 13, 2020 - The Latest Circuit Court Ruling on 340B Program Effect on Practices, Find out more
  • October 8, 2020 - On October 2, after consultation with public health officials, Department of Health and Human Services (HHS) Secretary Alex Azar, pursuant to the authority vested in him under section 319 of the Public Health Service Act, renewed the public health emergency effective October 23, 2020.
  • October 6, 2020 - Supreme Court scrutinizes Arkansas law that regulates PBM payments to pharmacies, Find out more

The Pfizer Oncology team has created a Speaker Program On Demand Site that now houses a program presented by Jennifer R. Klemp, PhD, MPH, entitled Addressing Cancer Health Disparities: Understanding Drivers and Looking Toward Change. This program is for healthcare professionals and illustrates the disparate health outcomes that exist across the cancer care continuum. The program provides an understanding of the factors contributing to healthcare disparities, the effect on health outcomes, and potential approaches to overcoming barriers that may negate optimal cancer care in vulnerable populations. Click here to review the program brochure.

Member News

Arun Bhandari, MDCSCO board member, has just been named to serve on the Maryland Health Care Commission. He also serves on the Maryland State Council of Cancer Control. Dr. Bhandari is with Chesapeake Oncology Hematology Associates in Annapolis.

ASCO Virtual Advocacy Day - September 16, 2020

Click here to view the attendees.